Journal of Substance Abuse Treatment
Volume 38, Issue 4 , Pages 338-345 , June 2010

High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin

  • Michael Waizmann, M.D.

      Affiliations

    • Corresponding Author InformationCorresponding author. MEDCENTER Leipzig, Karl-Tauchnitz-Str. 3, DE-04107 Leipzig, Germany. Tel.: +49 3 41 1 49 76 96; fax: +49 3 41 1 49 76 97.
    • ,
  • Grit Ackermann, M.D.

Received 1 October 2009 ,Revised 3 February 2010 ,Accepted 8 February 2010.

References 

  1. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. International Journal on Drug Policy. 2007;18:352–358
  2. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: A prospective, randomized, controlled trial. Clinical Infectious Diseases. 2007;45:770–778
  3. Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994–2004. Clinical Infectious Diseases. 2008;46:1852–1858
  4. Anagnostou O, Manolakopoulos S, Deutsch M, Tiniakou E, Giannaris M, Papatheodoridis G. Drug users with chronic hepatitis C who are adherent to antiviral treatment will finally benefit from therapy. Gastroenterology. 2008;134:A775
  5. Belfiori B, Ciliegi P, Chiodera A, Bacosi D, Tosti A, Baldelli F, et al. Peginterferon plus ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Digestive and Liver Disease. 2009;41:303–307
  6. Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC, Monto A, Rossi SJ, et al. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: Randomized comparison of direct observed therapy and self-administration. American Journal of Gastroenterology. 2008;103:2757–2765
  7. Chossegros P, Mélin P, Hézode C, Bourlière M, Pol S, Fhima A, et al. A French prospective observational study of the treatment of chronic hepatitis C in drug abusers. Gastroentérologie Clinique et Biologique. 2008;32:850–885
  8. Ciaccio A, Ferraro D, Alaimo G, Maggio AA, Craxi A, Almasio PL. Feasibility of combination therapy for chronic hepatitis C in IVDU in the framework of a heroin detoxification protocol. Hepatology. 2007;46:393A–394A
  9. Conway B, Prasad J, Reynolds R, Farley J, Jones M, Jutha S, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clinical Infectious Diseases. 2004;38:S402–S408
  10. de Bie J, Robaeys G, Buntinx F. Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): Guidelines for clinical practice. Acta Gastroenterologica Belg. 2005;68:68–80
  11. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics. 2003;44:104–112
  12. Dore GJ, Thomas DL. Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. Seminars in Liver Disease, 25, 18–32. Journal on Drug Policy. 2005;18:341–351
  13. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine. 2002;347:975–982
  14. Grebely J, Genoway K, Khara M, Duncan F, Viljoen M, Elliott D, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. International Journal on Drug Policy. 2007;18:437–443
  15. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine. 2004;140:346–355
  16. Hagan H, Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, et al. HCV synthesis project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. International Journal on Drug Policy. 2007;18:341–351
  17. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry. 2002;7:942–947
  18. Krook AL, Stokka D, Heger B, Nygaard E. Hepatitis C treatment of opioid dependants receiving maintenance treatment: Results of a Norwegian pilot study. European Addiction Research. 2007;13:216–221
  19. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities. Clinical Infectious Diseases. 2005;40:S339–345
  20. Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neuroscience Letters. 2004;365:87–91
  21. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clinical Infectious Diseases. 2006;42:1628–1635
  22. Lucas GM, Weidle PJ, Hader S, Moore RD. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: A nonrandomized comparative study. Clinical Infectious Diseases. 2004;38:S409–S413
  23. Martín-Santos R, Díez-Quevedo C, Castellví P, Navinés R, Miquel M, Masnou H. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Alimentary Pharmacology and Therapeutics. 2008;27:257–265
  24. Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, et al. Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS and Behaviour. 2008;12:284–293
  25. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004;40:120–124
  26. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–1069
  27. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. Journal of Affective Disorders. 2007;103:83–90
  28. NIH Consensus Statement on Management of Hepatitis C: 2002 . In: NIH Consensus State-of-the-Science Statements. Vol. 19:2002;p. 1–46
  29. Pellicelli AM, Barbaro G, Barbarini G, Soccorsi F CLEO Group. Management of chronic hepatitis in drug addicts: A systematic review. Clinical Therapeutics. 2008;159:41–49
  30. Raison CL, Woolwine BJ, Demetrashvili MF, Borisov AS, Weinreib R, Staab J, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharmacology and Therapeutics. 2007;25:1163–1174
  31. Robaeys G, Van Vlierberghe H, Matheï C, Van Ranst M, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. European Journal of Gastroenterology and Hepatology. 2006;18:159–166
  32. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443–451
  33. Schaefer M, Schmidt F, Horn M, Schmid-Wendtner MH, Volkenandt M. Depression during treatment with interferon alpha. Psychosomatics. 2004;45:176
  34. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. Journal of Hepatology. 2005;42:793–798
  35. Smith-Rohrberg D, Mezger J, Walton M, Bruce RD, Altice FL. Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. Acquired Immune Deficiency Syndrome. 2006;43:S48–53
  36. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171
  37. Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clinical Infectious Diseases. 2003;37:S315–322
  38. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. European Journal of Gastroenterology and Hepatology. 2007;19:741–747
  39. van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. American Journal of Gastroenterology. 2003;98:2281–2288

PII: S0740-5472(10)00029-2

doi: 10.1016/j.jsat.2010.02.002

Journal of Substance Abuse Treatment
Volume 38, Issue 4 , Pages 338-345 , June 2010

Article Tools

* Image Usage & Resolution